Sponsors › Sanofi

Sanofi

Every GLP‑1 and incretin trial, approval and scheduled result we hold for Sanofi, drawn from ClinicalTrials.gov and Drugs@FDA.

Sanofi is a commercial sponsor with 44 trials in the incretin class on file here, across 4 molecules. The programme is split between 6 early-stage trials and 38 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market. The next scheduled result is 2026-09-18.

Molecules

dulaglutide · exenatide · liraglutide · lixisenatide

Trials on file

44

Active trials

1

Results scheduled

1

Approved FDA submissions

0

Results due

Trials on file

All 44 incretin trials recorded for this sponsor, active first.